Table 1a Platelet response criteria evaluated

From: Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial

Platelet response criteria

Duration

Definition

IWG 2006 HI-P17

8 weeks

For patients with baseline platelets <100 × 109/l:

Baseline platelets >20 × 109/l, absolute increase of ⩾30 × 109/l

Baseline platelets <20 × 109/l, increase to >20 × 109/l and by ⩾100%

IWG 2000 Major11

8 weeksa

For patients with baseline platelets <100 × 109/l:

An absolute increase of ⩾30 × 109/l

For platelet transfusion-dependent patients, stabilization of platelet counts and platelet transfusion independence

IWG 2000 Minor11

8 weeksa

For patients with baseline platelets <100 × 109/l:

A ⩾50% increase in platelet count with an absolute increase >10 × 109/l but <30 × 109/l

Italian MDS group 10

 Complete (same as IWG AML 200318)

None

Platelet count >100 × 109/l and no bleeding

 Any

None

Baseline platelets >20 × 109/l, no bleeding and absolute increase of ⩾30 × 109/l

Baseline platelets <20 × 109/l, increase to >20 × 109/l and by at least 100%

 Durable

4 weeks

Continuous platelet response

CALGB19

None

⩾50% restitution of the initial deficit (to 140 × 109/l)

ITP20

None

Platelet count>50 × 109/l

  1. Abbreviations: AML, acute myeloid leukemia; CALGB, Cancer and Leukemia Group B; HI-P, hematologic improvement—platelet; ITP, immune thrombocytopenia; IWG, International Working Group; MDS, myelodysplastic syndrome.
  2. aAs platelets were measured every week in this trial, for IWG 2000 response measures, an 8-week duration was used for these analyses, rather than 2 months.
Back to article page